Latest news

Who says pharma events have to be all work and no play? Join us for an enjoyable break during CPhI 2023 on Wednesday, October 25th, starting at 16:00. Come socialize with Adalvo's bees and, if...

Adalvo is excited to announce the launch of Gabapentin ER 300/600 mg in South Korea, in collaboration with our sister company, Lotus. Our product is based on the reference...

Adalvo proudly acknowledges September as Pain Awareness Month, joining the global community in raising awareness about the challenges faced by individuals dealing with chronic pain. With a strong commitment to improving the...

We are pleased to announce our successful DCP submission for Empagliflozin 25mg film-coated tablets, which was developed in collaboration with one of our strategic partners. Our product has been developed...

Adalvo Ltd. (Adalvo) and Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced a collaboration agreement for Rifamycin SV with MMX® technology in Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA) and Latin America (LATAM) regions. Under...

Adalvo is pleased to announce a new collaboration with Eurofarma, a Brazilian-owned multinational pharmaceutical company that promotes access to health and quality of life with treatments at a fair price and profitable operations. This collaboration...

Adalvo is proud to announce the launch of our Q3 2023 Product Dossier. Offering an exclusive glimpse into the advancing strides we have made over the last quarter, reflecting Adalvo's unwavering dedication...

Adalvo is excited to announce the launch of Pomalidomide Hard Capsules 1/2/3/4mg in Canada. Our product is based on the reference brand, Pomalyst, and is indicated in the treatment of adult patients with...

Adalvo is thrilled to announce the expansion of its partnership with Teva, signing a licensing deal for a blockbuster small molecule in the oncology segment aimed at addressing rare diseases...

We are pleased to announce oursuccessful DCP submission for Pomalidomide Hard Capsules 1/2/3/4mg, upon expiry of the orphan market exclusivity. Our product is based on the reference brand, Imnovid, and is indicated...

Adalvo is proud to share a significant achievement in our pursuit to making a difference for patients around the world. Last week, the company successfully filed three distinct INN DCP applications for Azelastine+Fluticasone...

We are pleased to announce our successful DCP submission for Dapagliflozin 10mg film-coated tablets. This product has been developed in collaboration with one of our strategic partners. Our product has been...

Adalvo is pleased to announce oursuccessful DCP submission for Adapalene + Benzoyl Peroxide Gel. This product has been developed in collaboration with one of our strategic partners, based on the reference...

Adalvo are pleased to announce our successful DCP submission for Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray. The product has been developed...

Adalvo is thrilled to have successfully executed Dimethyl Fumarate 120/240mg Capsules in Mexico, with our esteemed partners, Corne. This successful execution marks a significant milestone in Adalvo's commitment to delivering competitive pharmaceutical solutions around...

Adalvo is delighted to highlight the expansion of its portfolio with the well-established Dimetindene Gel 0.1% (1mg/g). This product has been developed based on the reference brand Fenistil Gel, and is intended...

Adalvo is pleased to announce that the successful Pivotal BE Study for Brivaracetam Film Coated Tablets has been completed, and we are currently preparing for our DCP submission, scheduled for January 2024. Brivaracetam Film Coated...

We are pleased to announce our successful DCP submission for Desogestrel+Ethinylestradiol (0.15mg+0.02mg) film-coated tablets. This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients. Our Desogestrel+Ethinylestradiol...